Skip to main content
Equibles
AMGN logo

AMGN · Amgen Inc

Track AMGN — free

Use AMGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AMGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$421.51 -2.13 (-0.50%) At close · Sep 30
S&P 500 member Nasdaq-100 member Russell 1000 member Dow 30 member Rebalance outlook locked
Market Cap
$226.05B
Shares
540.63M
Volume · Sep 30 3.13M Avg daily vol (3M) 2.7M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$421.51 Open$424.01 Day$420.63–426.59 52W close$282.20–444.12 Avg vol 30d2.9M Short int14.1M · 2.6% float · 4.9d Short vol54% Last earningsAug 4, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Nov 3, 2026 Est · unconfirmed · in 5 wks
Latest filing: 10-Q
filed Aug 5, 2026
Q2 2026 earnings call transcript
call held Aug 4, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$38.09B
Trailing 12 months
Net income (TTM)
$8.74B
Trailing 12 months
Revenue growth YoY
+9.5%
Year over year
Operating margin
30.0%
Trailing 12 months
P / E (TTM)
26.3
Trailing earnings · reciprocal yield 3.8%
FCF yield
4.5%
TTM · current market cap
Return on invested capital
17.7%
Trailing 12 months
Net cash
−$43.31B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.6%
Year over year · more shares
Price change (1Y)
+54.6%
Trailing year
Short interest
2.6%
Latest settlement · 4.9 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Moderate
Market backdrop VIX 16.3 · calm Equity put/call 0.53
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +16%
above
Price vs 50-day avg +3%
above
RSI (14) 59
neutral
MACD trend Positive
52-week position 86%
near high
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Strong
1-month return −4%
trailing
6-month return +19%
trailing
YTD return +29%
this year
Relative strength +6%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $408 › 200d $364 — 50d above 200d
Institutional flow Accumulating
+0% holders QoQ · +178 funds added
Insider flow Distributing
Net -$4.1M over 90 days · 100% sells
Short interest Rising
2.60% of float · ▲ +8.4% MoM · 4.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
3,179 holders — near 3-yr high, broad support
Squeeze score 59
elevated · 0–100
Fundamentals
Excellent
Revenue growth +9%
Y/Y
EPS growth +88%
Y/Y
Free cash flow $8.1B
Valuation P/E 26
below peers
Buyback $6.8B
remaining
Balance sheet $45.5B
net debt
Quant / Vol
risk profile
Moderate
Volatility 29%
annualized · 1-yr
Max drawdown −17%
past year
ATR 2.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 6 of last 7
Latest guidance · from the 8-K filed Aug 4, 2026
Total revenues · full year 2026 Initiated $38.2B – $39.4B
prior FY $36.75B midpoint +5.6% Y/Y
GAAP EPS · full year 2026 Initiated $15.80 – $17.08
prior FY $14.23 midpoint +15.5% Y/Y
Non-GAAP EPS · full year 2026 Initiated $22.30 – $23.50
GAAP tax rate · full year 2026 Initiated 14.5% – 16%
Non-GAAP tax rate · full year 2026 Initiated 15% – 16.5%
Capital expenditures · full year 2026 Initiated $2.6B
Share repurchases · full year 2026 Initiated up to $3B
Guided vs delivered · last 7 settled
Total revenues full year 2024
guided $32.8B – $33.8B
$33.42B In line
EPS full year 2024
guided $6.57 – $7.62
$7.56 In line
Total revenues full year 2023
guided $28B – $28.4B
$28.19B In line
EPS full year 2023
guided $11.23 – $12.73
$12.49 In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 2 · 5
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+16% Bullish
Price vs 50-day avg
+3% Bullish
RSI (14)
59 Neutral
MACD trend
Positive Bullish
52-week position
86% Bullish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $408 › 200d $364 — 50d above 200d
Institutional flow Accumulating
+0% holders QoQ · +178 funds added
Insider flow Distributing
Net -$4.1M over 90 days · 100% sells
Short interest Rising
2.60% of float · ▲ +8.4% MoM · 4.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
3,179 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $282 Now $422 · 86% Range high $444
vs 200-day avg +16% vs 50-day avg +3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Drug Manufacturers - General — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AMGN
Amgen Inc
this stock
$226.05B +28.8% +8.8% 26.0 2.6%
LLY
ELI LILLY & Co
 $1.11T +7.7% +44.7% 39.7 0.8%
JNJ
Johnson & Johnson
 $653.61B +27.9% +6.0% 31.5 0.9%
ABBV
AbbVie Inc.
 $466.80B +14.5% +8.6% 74.6 1.1%
MRK
Merck & Co., Inc.
 $367.07B +38.0% +1.3% 119.0 1.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
3,179
% held
84.5%
Net QoQ
+13.6M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
1,226
View
Short & Settlement
Short Interest Rising
Shares short
14.1M
Days to cover
4.9d
Change
+1.1M sh
View
Short Volume
Short vol %
54%
As of
Sep 30, 2026
Short Total
View
Fails to Deliver
FTD shares
1.2K
Value
$472.4K
As of
Sep 11, 2026
View
Off-Exchange
Off-exchange %
47.6%
Week of
Aug 24, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$4.1M
Buyers / Sellers
0 / 3
Buyers Sellers
View
Congressional Trades Buy
Member
David J. Taylor
Amount
$1.0K–$15.0K
Traded
Jun 5, 2026
View
Financials
Financials
Revenue (FY)
$36.8B
Net income (FY)
$7.7B
EPS diluted
$14.23
View
Buybacks
Remaining
$6.8B
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Sep 6, 2026
This year
14
View
Proposed Sales
Value
$516.8K
Shares
1.3K
Filed
Aug 13, 2026
View
Earnings & Events
Earnings Calls
Last call
Sep 6, 2026
View

Performance

5D 20D 120D MTD YTD
AMGN +3.8% -3.8% +18.5% -2.0% +28.8%
SPY -0.7% +0.1% +12.2% -0.6% +11.8%
vs SPY +4.5% -3.9% +6.4% -1.4% +16.9%

Capital returns

Buyback program · as of Jun 30, 2026
Authorized
—
Spent (derived)
—
Remaining
$6.80B

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 318154 CUSIP 031162100 13F (30d) 80 filings 35 filers Visit website Investor relations